Reaction Details Report a problem with these data
Target
Mitogen-activated protein kinase 14
Ligand
BDBM50374614
Substrate
n/a
Meas. Tech.
ChEMBL_469610 (CHEMBL934189)
IC50
>10000±n/a nM
Citation
 Martin, MW; Newcomb, J; Nunes, JJ; Boucher, C; Chai, L; Epstein, LF; Faust, T; Flores, S; Gallant, P; Gore, A; Gu, Y; Hsieh, F; Huang, X; Kim, JL; Middleton, S; Morgenstern, K; Oliveira-dos-Santos, A; Patel, VF; Powers, D; Rose, P; Tudor, Y; Turci, SM; Welcher, AA; Zack, D; Zhao, H; Zhu, L; Zhu, X; Ghiron, C; Ermann, M; Johnston, D; Saluste, CG Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 51:1637-48 (2008) [PubMed]  Article 
Target
Name:
Mitogen-activated protein kinase 14
Synonyms:
CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta
Type:
Serine/threonine-protein kinase
Mol. Mass.:
41286.76
Organism:
Homo sapiens (Human)
Description:
Q16539
Residue:
360
Sequence:
MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES
  
Inhibitor
Name:
BDBM50374614
Synonyms:
CHEMBL254674
Type:
Small organic molecule
Emp. Form.:
C29H23Cl3N8O
Mol. Mass.:
605.905
SMILES:
CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c4ccccc4nc2n(-c2c(Cl)cc(Cl)cc2Cl)c3=O)cc1 |(13.38,-19.23,;14.71,-20,;16.05,-19.24,;17.38,-20.01,;17.37,-21.55,;16.04,-22.32,;14.71,-21.55,;18.7,-22.32,;20.04,-21.55,;21.37,-22.32,;21.36,-23.86,;22.69,-24.63,;24.03,-23.87,;24.03,-22.32,;25.35,-21.55,;26.7,-22.31,;26.69,-23.86,;25.36,-24.64,;28.03,-24.63,;28.35,-26.13,;27.44,-27.37,;28.06,-28.77,;29.59,-28.94,;30.49,-27.7,;29.88,-26.3,;30.51,-24.9,;29.37,-23.86,;29.37,-22.32,;30.7,-21.55,;30.7,-20.01,;29.36,-19.25,;32.03,-19.24,;33.37,-20.02,;34.7,-19.25,;33.37,-21.56,;32.03,-22.32,;32.03,-23.86,;28.03,-21.54,;28.03,-20,;20.04,-24.63,;18.71,-23.87,)|
Structure:
Search PDB for entries with ligand similarity: